SlideShare a Scribd company logo
Young-Chan KIM
Director General
Pharmaceuticals Safety Bureau
Korea Food and Drug Administration
1. Current Status and Outlook of Global
Pharmaceutical Market
A. World Pharmaceutical Industry
Global pharmaceutical market size in ’05
602 trillion KRW with 10% annual growth rate
Steady growth is expected
Expected to be 900 trillion KRW by 2010
Global Pharmaceutical Market (in trillion)
1998 1999 2000 2001 2002 2003 2004 2005
Global
Market
(KRW)
298 331 356 390 427 497 559 602
Growth
Rate
7% 11% 11% 13% 9% 10% 8% 7%
Sources: IMS health, IMS MIDAS, Quantum
B. Market Status in Major Regions
Market leaders
U.S.A. with 45% of global market share
Europe: Germany, France, England, and Italy
Japan with 11% of market share, 60 trillion KRW
China with the highest growth rate: 30%
Country
Market Size
(trillion KRW)
Market Share
(%)
Growth Rate for Past 12
month (%)
U.S.A. 246.4 44.7 7
Germany 31.2 5.7 6
France 30.3 5.5 7
England 20.3 3.7 3
Italy 19.4 3.5 0
Japan 60 10.9 3
China 17 2.8 30
Market Share Status in 2005
Japan : 11 of world’s 50 largest companies, such as Takeda
China : Fast market growth ( Increased 28% from 2004 to 2005)
C. Outlook
• Steady increase of medical expenses:
– The price of medicine, due to the aging society
– Spread of well-being trend, improvement in quality of life as
household income increases
– Expanding demand in Quality of Life Drug for chronic diseases
such as obesity, hypertension, erectile dysfunction, and diabetes
• Expects rapid growth of natural substance based drugs, due to
the expansion of preventive and alternative medicine usage
2. Pharmaceutical Industry in Korea
A. General Status
When compared with GDP, Korea's medical expense is lower
than other OECD members (6%)
Compared with medical price, it is the highest (28%)
With increase of income and change of life style, Korean
pharmaceutical market is pursuing Quality of Life Drug, like
other developed countries
B. History of Domestic Pharmaceutical Industry
Secured medical technology in 1960's
Established domestic drugs from materials in 1970's
Started to develop new drugs in late 1980's
Development of antibiotics was major focus until 90's
Development of geriatric drug after 2000
Hereafter, to enhance the quality of life, obesity, alopecia, and
erectile dysfunction drugs will be the major development of
domestic pharmaceutical industry.
History of New Drug R&D in Korea
Antibiotics
(1980’s ~ 1990’s)
Drugs for diseases caused
by living habit
(1990’s ~ Present)
QOL Drugs
(2000’s and after)
Decrease of antibiotic
1980’s: 20%
2001: 15%
Due to brief treatment
period for antibiotics, they
have shorter expiration
date
Transition from infection
treatment drug based
market to chronic and
geriatric drug based market
(Larger emphasis on
chronic and geriatric
diseases, such as
hypertension and diabetes)
To follow current life
trend, rapid growth of
QOL drugs, rather than life
related drugs
Along with growth of
technology, vast possibility
of development of erectile
dysfunction, obesity and
alopecia drugs
C. Market size and its structure
• Total production of domestic drug market: 9.6 trillion KRW in 2004,
11.3 trillion KRW in 2006 (Actual product sales)
– 1.3% of GDP
– 1.8% of global market, 11th largest market and rapidly growing.
Domestic Market in Global Pharmaceutical Market
Year 2000 2001 2002 2003 2004
Share 2.2% 1.8% 1.8% 1.7% 1.8%
Sources: Global market, IMS Health, 2005; Korean market, actual product sales in Korea pharmaceutical
manufactures association, 2005
D. Development of New Drugs
• Major development of new drugs after introduction of “Material
Patent System” in 1987
– “Sunpla inj.” (SK Pharmaceuticals, ‘99) First domestically
developed drug
– “Factive” (LG Life Science) FDA approved (April, ‘03)
– As of 2007
• Total of 15 drugs were domestically developed and about 40 technologies exported.
• Clinical trial for new drugs: about 30 cases
• Pre-clinical trial in process: 25 cases
• With approval of FDA (U.S.A.), 5~6 new drugs are in clinical trials
New Development Projects for Major Korean Companies
Products Stages # Products # Companies
Phase I 7 7
Phase II 11 9Clinical Trial
Phase III 12 7
Preclinical 50 25
New Drugs
Discovery 28 14
Others
New formulations /Combinations
/DDS
75 33
Biotech Medicines 26 16
Achievement of New Drug R&D in Korea
Indication / Efficacy
No. Product Company Approved date
1 Sunpla injection SK chemicals Stomach cancer Sep. 1999
2 EGF topical solution Daewoong Pharm. Co., Ltd. Diabetic antiulcerant May. 2001
3 Milican Dong Wha Pharm. Anti Liver Cancer July. 2001
4 Q-roxin Tablet
ChoongWae Pharma
Corporation
Urinary infection Feb. 2001
5 Joins Tablet SK chemicals Antiarthritis July. 2001
6 Stillen Capsule Dong-A Pharm. Co.,Ltd. Gastritis June. 2002
7 Factive Tablet LG Life Sciences Ltd. Antibiotic Dec. 2002
8 Apitoxin GuJu Pharm. Co., Ltd. Antiarthritis May. 2003
9 Pseudovaxin injection CJ Pseudomonas aeruginosa May. 2003
10 Camtobell injection
Chong Kun Dang Pharm.
Corp.
Anticancer Jan. 2003
11 Revanex Tablet YUHAN Corporation Antiulcer Sep. 2005
12 Zydena Tablet Dong-A Pharm. Co.,Ltd. Erectile Dysfunction Nov. 2005
13 Levovir Capsule Bukwang Pharm.Co.,Ltd. Hepatitis B Nov. 2006
14 Mvix Tablet SK chemicals Erectile Dysfunction July. 2007
Joins Tab., Stillen Tab., and Apitoxin have been classified as natural substance based drugs, and have been excluded from
cell treatment
E. Infrastructure of Clinical Trials
• Established “Good Clinical Practices” in December 1987
• Mandatory in October, 1995
– Adopted ICH GCP standard in Jan. 2000, reinforced subject’s right,
its safety protection and the liability of the testers
– IND (Investigational new Drug Application) became effective in
dec. 2002, establishing the founding stone of Global Harmonization
• Total 16 preclinical testing facilities (GLP appointed) for
new drug development, and 3 facilities with ability to
conduct all stages of the test
• Clinical trials is conducted in 119 institutions
Current Status of Preclinical Trial October 2008.3
NO SITE
1 KOREA INSTITUTE OF TOXICOLOGY
2 YUHAN RESEARCH INSTITUTE
3 LG LIFE SCIENCES RESEARCH INSTITUTE
4 BIOTOXTECH
5 OCCUPATIONAL SAFETY AND HEALTH RESEARCH INSTITUTE
6 CHEMON PRECLINICAL RESEARCH CENTER
7 AMOREPACIFIC R&D CENTER
8 CLINICAL RESEARCH INSTITUTE SEOUL NATIONAL UNIVERSITY HOSPITAL
9 KOREA TESTING & RESEARCH INSTITUTE
10 MEDVILL
11 BIOCORE
12 IBIOPHARM
13 CENTER FOR BIOSAFETY CATHOLIC UNIVERSITY OF DAEGU
14 CLINICAL RESEARCH INSTITUTE DONGA UNIVERSITY MEDICAL CENTER
15 SEOUL PHARMA LABORATORIES
16 KOREA ENVIRONMENT & MERCHANDISE TESTING INSTITUTE
• Established global level infrastructure of clinical trials, along with
active development of new drugs and discovery of replacement
drugs by the pharmaceutical companies and new venture life
science firms
– With the increase of global clinical trials, domestic trials also
increase rapidly
Clinical Trial Status (Numbers of Practice)
2001 2002 2003 2004 2005 2006 2007
Total 45 55 143 136 185 218 281
Domestic
Trials
27 38 97 75 90 110 134
Others 18 17 46 61 95 108 147
New Drug Development Cases in Korea(1)
• Small molecules, approved by FDA
– Brand name : Factive tablet/Tablets (Ethical drug)
– Company : LG Life Science
– Active Ingredient : gemifloxacin mesylate
– Indication : synthetic broad-spectrum antibacterial agent
– Dosage & Administration :
Acute bacterial exacerbation of chronic bronchitis :
DOSE-One 320mg tablet daily / DURATION-5 days
Community-acquired pneumonia :
DOSE-One 320mg tablet daily / DURATION-7 days
New Drug Development Cases in Korea(2)
• Success of natural substance based development, derived from
traditional medicine
– Brand name : Stillen Capsules/Tablets (Ethical drug)
– Company : Dong-A Pharmaceutical.
– Active Ingredient : Extract of Artemisia princeps 60mg
– Indication : Gastrointestinal diseases
(Gastritis, Prevention of gastritis by NSAID)
– Dosage & Administration : 1Tab. Three times daily
– Sales : 60 billion KRW in 2007
3. Assessment of Korea’s New Drug Development
• One new product every year since 2000
– Products are mostly sold in domestic market
– Drugs based on natural substances are more compatible than
chemical based
• New drugs are developed from initial research stages and
showed maximization of potential for successful
development
– There are limits due to its prolonged time and high risk
– Most of the projects in initial research stages are funded by
the government
• Infrastructure of clinical test has been evaluated to have
global competitiveness
– Infrastructure needs to be expanded for continuous
development of new drugs
To contribute to Asian’s health and the region’s
economic growth, through maximizing Korean
pharmaceutical industry’s strength and
complementing its weaknesses
From a future-oriented and a long term point of view,
Korea, China and Japan need to establish their
cooperation by amplifying their similarities and the
strengths
4. Direction of Global Development with
Korea, China and Japan
A. Establish a system to deliver new drugs to the patients
immediately among the three nations
B. Differentiate from U.S.A., Europe and Japan centered ICH, and
shape Global Development with enhanced regional
characteristics
– Recognize the differences among countries, but suggests that
its direction of pharmaceutical industry of the three countries
while presenting a future plan
– Develop a plan to utilize geographic proximity, cultural and
ethnic similarity for global development of science
• For global harmonization, Korea has implemented regulations
regarding clinical and preclinical trials, authorization (IND, NDA)
and production (DMF, GMP) to amend ICH’s suggested guidelines
for quality, safety and validity.
• Korea has announced “Development of the Pharmaceutical Industry
as a New Growth Power” as a government project, promoting
global harmonization of the pharmaceutical industry.
6. Role of KFDA
Continual pursuit of global harmonization: implementation of
ICH guidelines
– Introduced ICH GCP (Currently enforced)
– Introduced OECD GLP standard (Currently enforced)
– DMF system, upgraded cGMP standard (Currently enforced)
– Introduced CTD system (Plan to enforce in March ’09 with
new drugs)
Discovery of Eastern Values: Focus of Korea, China and
Japan’s cooperation
– Develop plan to reflect Eastern values such as natural substa
nce, herbal medicine, etc.
– Reflect Asian experience through cooperation of Korea,
China, and Japan
Share technology and experience centered Asian clinical trial
– Participate in expedited new medicine development through
cooperative clinical trial among Korea, China, and Japan in
order to provide a scientific explanation for differences in
ethnicities
Cooperation for holding a joint seminar among Korea, China,
and Japan pharmaceutical associations and regulatory
organizations
Operate a Korean professional group to seek Korea, China, and
Japan cooperation plan through a Korean professional group
– Herbal and natural substance medicine division
– Korea, China, and Japan cooperative clinical trial, cross-bridge
division
• Search for scientific explanation for ethnic differences
– Review Process division
– Regulation and system harmonization division
Thank You

More Related Content

What's hot

Us registration for foreign drugs
Us registration for foreign drugsUs registration for foreign drugs
Us registration for foreign drugs
Niva Rani Gogoi
 
Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)
TGA Australia
 
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company
Debashish Kar
 
4th sem copy
4th sem copy4th sem copy
4th sem copy
Doninder Hooda
 
MentLife, Drug Discovery, Development & Trends, nov 6 2013
MentLife, Drug Discovery, Development & Trends, nov 6 2013MentLife, Drug Discovery, Development & Trends, nov 6 2013
MentLife, Drug Discovery, Development & Trends, nov 6 2013
MentLife
 
Biosimilars-emerging market in india
Biosimilars-emerging market in indiaBiosimilars-emerging market in india
Biosimilars-emerging market in india
PRUTHVIRAJ. U
 
Biosimilars Webinar June 29, 2016 Slides
Biosimilars Webinar June 29, 2016 SlidesBiosimilars Webinar June 29, 2016 Slides
Biosimilars Webinar June 29, 2016 Slides
Canadian Organization for Rare Disorders
 
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological ProductsFDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
MedicReS
 
generic drugs
generic drugs generic drugs
generic drugs
Rupali Panchadhaye
 
Regulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy IIRegulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy II
Jafarali Masi
 
IMPD + IB
IMPD + IBIMPD + IB
IMPD + IB
Snehankit Gurjar
 
Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...
TGA Australia
 
A Study of generic drugs
A Study of generic drugsA Study of generic drugs
A Study of generic drugs
Santosh Salgare
 
INDs: When Required and Contents
INDs: When Required and ContentsINDs: When Required and Contents
INDs: When Required and Contents
Louise666
 
Biosimilars: Regulation Issues
Biosimilars: Regulation Issues Biosimilars: Regulation Issues
Biosimilars: Regulation Issues
Joseph Pategou
 
Development of Ritux Biosimilar
Development of Ritux BiosimilarDevelopment of Ritux Biosimilar
Development of Ritux Biosimilar
Pilar Nava-Parada
 
Drug approval in US, EU & India
Drug approval in US, EU & IndiaDrug approval in US, EU & India
Drug approval in US, EU & India
Sweta Yadav
 
R&D Productivity and Costs in Today's Health Care Arena - Pat Audet
R&D Productivity and Costs in Today's Health Care Arena - Pat AudetR&D Productivity and Costs in Today's Health Care Arena - Pat Audet
R&D Productivity and Costs in Today's Health Care Arena - Pat Audet
TTC, llc
 
FDA Presentation on Biologics
FDA Presentation on BiologicsFDA Presentation on Biologics
FDA Presentation on Biologics
Robert Puopolo
 
The Importance of Developing a Global Regulatory Strategy towards the Goal of...
The Importance of Developing a Global Regulatory Strategy towards the Goal of...The Importance of Developing a Global Regulatory Strategy towards the Goal of...
The Importance of Developing a Global Regulatory Strategy towards the Goal of...
Life Sciences Network marcus evans
 

What's hot (20)

Us registration for foreign drugs
Us registration for foreign drugsUs registration for foreign drugs
Us registration for foreign drugs
 
Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)Module 3 requirements for Biologics (peptide/protein medicines)
Module 3 requirements for Biologics (peptide/protein medicines)
 
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company
 
4th sem copy
4th sem copy4th sem copy
4th sem copy
 
MentLife, Drug Discovery, Development & Trends, nov 6 2013
MentLife, Drug Discovery, Development & Trends, nov 6 2013MentLife, Drug Discovery, Development & Trends, nov 6 2013
MentLife, Drug Discovery, Development & Trends, nov 6 2013
 
Biosimilars-emerging market in india
Biosimilars-emerging market in indiaBiosimilars-emerging market in india
Biosimilars-emerging market in india
 
Biosimilars Webinar June 29, 2016 Slides
Biosimilars Webinar June 29, 2016 SlidesBiosimilars Webinar June 29, 2016 Slides
Biosimilars Webinar June 29, 2016 Slides
 
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological ProductsFDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
FDA 2013 Clinical Investigator Training Course: Biosimilar Biological Products
 
generic drugs
generic drugs generic drugs
generic drugs
 
Regulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy IIRegulatory requirements for drug approval - industrial pharmacy II
Regulatory requirements for drug approval - industrial pharmacy II
 
IMPD + IB
IMPD + IBIMPD + IB
IMPD + IB
 
Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...Regulation, ethics and reimbursement of novel biological therapies in Austral...
Regulation, ethics and reimbursement of novel biological therapies in Austral...
 
A Study of generic drugs
A Study of generic drugsA Study of generic drugs
A Study of generic drugs
 
INDs: When Required and Contents
INDs: When Required and ContentsINDs: When Required and Contents
INDs: When Required and Contents
 
Biosimilars: Regulation Issues
Biosimilars: Regulation Issues Biosimilars: Regulation Issues
Biosimilars: Regulation Issues
 
Development of Ritux Biosimilar
Development of Ritux BiosimilarDevelopment of Ritux Biosimilar
Development of Ritux Biosimilar
 
Drug approval in US, EU & India
Drug approval in US, EU & IndiaDrug approval in US, EU & India
Drug approval in US, EU & India
 
R&D Productivity and Costs in Today's Health Care Arena - Pat Audet
R&D Productivity and Costs in Today's Health Care Arena - Pat AudetR&D Productivity and Costs in Today's Health Care Arena - Pat Audet
R&D Productivity and Costs in Today's Health Care Arena - Pat Audet
 
FDA Presentation on Biologics
FDA Presentation on BiologicsFDA Presentation on Biologics
FDA Presentation on Biologics
 
The Importance of Developing a Global Regulatory Strategy towards the Goal of...
The Importance of Developing a Global Regulatory Strategy towards the Goal of...The Importance of Developing a Global Regulatory Strategy towards the Goal of...
The Importance of Developing a Global Regulatory Strategy towards the Goal of...
 

Viewers also liked

How to use social media for customer engagement for accountants
How to use social media for customer engagement for accountantsHow to use social media for customer engagement for accountants
How to use social media for customer engagement for accountants
Mark Appel
 
Social Media voor Accountants
Social Media voor AccountantsSocial Media voor Accountants
Social Media voor Accountants
Mark Appel
 
Mvix General
Mvix GeneralMvix General
Mvix General
Mark Appel
 
Serendipity UI & IxD Commodore
Serendipity UI & IxD CommodoreSerendipity UI & IxD Commodore
Serendipity UI & IxD Commodore
Mark Appel
 
Exact DIGITAL BUSINESS PLATFORM
Exact DIGITAL BUSINESS PLATFORMExact DIGITAL BUSINESS PLATFORM
Exact DIGITAL BUSINESS PLATFORM
Mark Appel
 
New CDS Digital Signage Brochure 2017
New CDS Digital Signage Brochure 2017New CDS Digital Signage Brochure 2017
New CDS Digital Signage Brochure 2017
Chris Bartram, Digital Displays Specialist
 
Adulteration of drugs
Adulteration of drugsAdulteration of drugs
MCSi Digital Signage Presentation
MCSi Digital Signage PresentationMCSi Digital Signage Presentation
MCSi Digital Signage Presentation
Gary Quasebarth
 

Viewers also liked (8)

How to use social media for customer engagement for accountants
How to use social media for customer engagement for accountantsHow to use social media for customer engagement for accountants
How to use social media for customer engagement for accountants
 
Social Media voor Accountants
Social Media voor AccountantsSocial Media voor Accountants
Social Media voor Accountants
 
Mvix General
Mvix GeneralMvix General
Mvix General
 
Serendipity UI & IxD Commodore
Serendipity UI & IxD CommodoreSerendipity UI & IxD Commodore
Serendipity UI & IxD Commodore
 
Exact DIGITAL BUSINESS PLATFORM
Exact DIGITAL BUSINESS PLATFORMExact DIGITAL BUSINESS PLATFORM
Exact DIGITAL BUSINESS PLATFORM
 
New CDS Digital Signage Brochure 2017
New CDS Digital Signage Brochure 2017New CDS Digital Signage Brochure 2017
New CDS Digital Signage Brochure 2017
 
Adulteration of drugs
Adulteration of drugsAdulteration of drugs
Adulteration of drugs
 
MCSi Digital Signage Presentation
MCSi Digital Signage PresentationMCSi Digital Signage Presentation
MCSi Digital Signage Presentation
 

Similar to 2008 global development korea's perspective and the role of kfda

Conducting clinical trials in japan chris merriam-leith
Conducting clinical trials in japan   chris merriam-leithConducting clinical trials in japan   chris merriam-leith
Conducting clinical trials in japan chris merriam-leith
Chris Merriam-Leith, MS, PMP, RAC
 
schedule y of drugs and cosmetic acts
schedule y of drugs and cosmetic actsschedule y of drugs and cosmetic acts
schedule y of drugs and cosmetic acts
arponbiswas
 
1 drug developmentv1
1 drug developmentv11 drug developmentv1
1 drug developmentv1
ionessy
 
US Medical Research And Dvt
US Medical Research And DvtUS Medical Research And Dvt
US Medical Research And Dvt
MedipharmaNetwork
 
Application of bio-pharmaceutics in new drug development .
Application of bio-pharmaceutics in new drug development .Application of bio-pharmaceutics in new drug development .
Application of bio-pharmaceutics in new drug development .
MD SAYDUR RAHMAN
 
Introduction to pharmaceutical industry & clinical research
Introduction to pharmaceutical industry & clinical researchIntroduction to pharmaceutical industry & clinical research
Introduction to pharmaceutical industry & clinical research
Bhaswat Chakraborty
 
Statistics-in-Drug-Development-2015-UC-BS.pptx
Statistics-in-Drug-Development-2015-UC-BS.pptxStatistics-in-Drug-Development-2015-UC-BS.pptx
Statistics-in-Drug-Development-2015-UC-BS.pptx
DiptoKumerSarker1
 
Clinical studies – a primer
Clinical studies – a primerClinical studies – a primer
Clinical studies – a primer
Moshe Ben Yitzhak
 
Schedule Y Summary
Schedule Y SummarySchedule Y Summary
Schedule Y Summary
Shrinath Sonwane
 
Economics of drug discovery. final.pptx
Economics of drug discovery. final.pptxEconomics of drug discovery. final.pptx
Economics of drug discovery. final.pptx
ashharnomani
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agencies
Urmila Aswar
 
Acetogenins In Vivo re: Wu - (p 22-36)
Acetogenins In Vivo re: Wu - (p 22-36)Acetogenins In Vivo re: Wu - (p 22-36)
Acetogenins In Vivo re: Wu - (p 22-36)
Ben Rockefeller
 
Schedule y draft 2
Schedule y draft 2Schedule y draft 2
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
Sujith Thokala
 
Summary Of Schedule Y
Summary Of Schedule YSummary Of Schedule Y
Summary Of Schedule Y
lekshmilnair
 
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLSDiscovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Katalyst HLS
 
Schedule Y
Schedule YSchedule Y
Schedule Y
Richa Patel
 
Primary biliary cholangitis (PBC) Epidemiology and Compitive landscape_Thelan...
Primary biliary cholangitis (PBC) Epidemiology and Compitive landscape_Thelan...Primary biliary cholangitis (PBC) Epidemiology and Compitive landscape_Thelan...
Primary biliary cholangitis (PBC) Epidemiology and Compitive landscape_Thelan...
Thelansis
 
Tony Lockett May 2016 CV
Tony Lockett May 2016 CVTony Lockett May 2016 CV
Tony Lockett May 2016 CV
anthony lockett
 
Regulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug ApprovalRegulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug Approval
Shagufta Farooqui
 

Similar to 2008 global development korea's perspective and the role of kfda (20)

Conducting clinical trials in japan chris merriam-leith
Conducting clinical trials in japan   chris merriam-leithConducting clinical trials in japan   chris merriam-leith
Conducting clinical trials in japan chris merriam-leith
 
schedule y of drugs and cosmetic acts
schedule y of drugs and cosmetic actsschedule y of drugs and cosmetic acts
schedule y of drugs and cosmetic acts
 
1 drug developmentv1
1 drug developmentv11 drug developmentv1
1 drug developmentv1
 
US Medical Research And Dvt
US Medical Research And DvtUS Medical Research And Dvt
US Medical Research And Dvt
 
Application of bio-pharmaceutics in new drug development .
Application of bio-pharmaceutics in new drug development .Application of bio-pharmaceutics in new drug development .
Application of bio-pharmaceutics in new drug development .
 
Introduction to pharmaceutical industry & clinical research
Introduction to pharmaceutical industry & clinical researchIntroduction to pharmaceutical industry & clinical research
Introduction to pharmaceutical industry & clinical research
 
Statistics-in-Drug-Development-2015-UC-BS.pptx
Statistics-in-Drug-Development-2015-UC-BS.pptxStatistics-in-Drug-Development-2015-UC-BS.pptx
Statistics-in-Drug-Development-2015-UC-BS.pptx
 
Clinical studies – a primer
Clinical studies – a primerClinical studies – a primer
Clinical studies – a primer
 
Schedule Y Summary
Schedule Y SummarySchedule Y Summary
Schedule Y Summary
 
Economics of drug discovery. final.pptx
Economics of drug discovery. final.pptxEconomics of drug discovery. final.pptx
Economics of drug discovery. final.pptx
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agencies
 
Acetogenins In Vivo re: Wu - (p 22-36)
Acetogenins In Vivo re: Wu - (p 22-36)Acetogenins In Vivo re: Wu - (p 22-36)
Acetogenins In Vivo re: Wu - (p 22-36)
 
Schedule y draft 2
Schedule y draft 2Schedule y draft 2
Schedule y draft 2
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 
Summary Of Schedule Y
Summary Of Schedule YSummary Of Schedule Y
Summary Of Schedule Y
 
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLSDiscovery of Drug and Introduction to Clinical Trial__Katalyst HLS
Discovery of Drug and Introduction to Clinical Trial__Katalyst HLS
 
Schedule Y
Schedule YSchedule Y
Schedule Y
 
Primary biliary cholangitis (PBC) Epidemiology and Compitive landscape_Thelan...
Primary biliary cholangitis (PBC) Epidemiology and Compitive landscape_Thelan...Primary biliary cholangitis (PBC) Epidemiology and Compitive landscape_Thelan...
Primary biliary cholangitis (PBC) Epidemiology and Compitive landscape_Thelan...
 
Tony Lockett May 2016 CV
Tony Lockett May 2016 CVTony Lockett May 2016 CV
Tony Lockett May 2016 CV
 
Regulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug ApprovalRegulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug Approval
 

More from patyi_2000

2009 korea-s-bt-pharm-industry
2009 korea-s-bt-pharm-industry2009 korea-s-bt-pharm-industry
2009 korea-s-bt-pharm-industry
patyi_2000
 
2009 korea lifescience resource_guidebook2009
2009 korea lifescience resource_guidebook20092009 korea lifescience resource_guidebook2009
2009 korea lifescience resource_guidebook2009
patyi_2000
 
2008 promising investment opportunities korea
2008 promising investment opportunities korea 2008 promising investment opportunities korea
2008 promising investment opportunities korea
patyi_2000
 
2008 promising investment korta
2008 promising investment korta2008 promising investment korta
2008 promising investment korta
patyi_2000
 
Biopharmaceutical march 2015
Biopharmaceutical march 2015Biopharmaceutical march 2015
Biopharmaceutical march 2015
patyi_2000
 
Biopharmaceutical industry kotra march_20151
Biopharmaceutical industry kotra march_20151Biopharmaceutical industry kotra march_20151
Biopharmaceutical industry kotra march_20151
patyi_2000
 
Quintiles william blair-35th-annual-growth-stock-conference
Quintiles william blair-35th-annual-growth-stock-conferenceQuintiles william blair-35th-annual-growth-stock-conference
Quintiles william blair-35th-annual-growth-stock-conference
patyi_2000
 
99580907 global-cro-report
99580907 global-cro-report99580907 global-cro-report
99580907 global-cro-report
patyi_2000
 

More from patyi_2000 (8)

2009 korea-s-bt-pharm-industry
2009 korea-s-bt-pharm-industry2009 korea-s-bt-pharm-industry
2009 korea-s-bt-pharm-industry
 
2009 korea lifescience resource_guidebook2009
2009 korea lifescience resource_guidebook20092009 korea lifescience resource_guidebook2009
2009 korea lifescience resource_guidebook2009
 
2008 promising investment opportunities korea
2008 promising investment opportunities korea 2008 promising investment opportunities korea
2008 promising investment opportunities korea
 
2008 promising investment korta
2008 promising investment korta2008 promising investment korta
2008 promising investment korta
 
Biopharmaceutical march 2015
Biopharmaceutical march 2015Biopharmaceutical march 2015
Biopharmaceutical march 2015
 
Biopharmaceutical industry kotra march_20151
Biopharmaceutical industry kotra march_20151Biopharmaceutical industry kotra march_20151
Biopharmaceutical industry kotra march_20151
 
Quintiles william blair-35th-annual-growth-stock-conference
Quintiles william blair-35th-annual-growth-stock-conferenceQuintiles william blair-35th-annual-growth-stock-conference
Quintiles william blair-35th-annual-growth-stock-conference
 
99580907 global-cro-report
99580907 global-cro-report99580907 global-cro-report
99580907 global-cro-report
 

2008 global development korea's perspective and the role of kfda

  • 1. Young-Chan KIM Director General Pharmaceuticals Safety Bureau Korea Food and Drug Administration
  • 2. 1. Current Status and Outlook of Global Pharmaceutical Market A. World Pharmaceutical Industry Global pharmaceutical market size in ’05 602 trillion KRW with 10% annual growth rate Steady growth is expected Expected to be 900 trillion KRW by 2010 Global Pharmaceutical Market (in trillion) 1998 1999 2000 2001 2002 2003 2004 2005 Global Market (KRW) 298 331 356 390 427 497 559 602 Growth Rate 7% 11% 11% 13% 9% 10% 8% 7% Sources: IMS health, IMS MIDAS, Quantum
  • 3. B. Market Status in Major Regions Market leaders U.S.A. with 45% of global market share Europe: Germany, France, England, and Italy Japan with 11% of market share, 60 trillion KRW China with the highest growth rate: 30% Country Market Size (trillion KRW) Market Share (%) Growth Rate for Past 12 month (%) U.S.A. 246.4 44.7 7 Germany 31.2 5.7 6 France 30.3 5.5 7 England 20.3 3.7 3 Italy 19.4 3.5 0 Japan 60 10.9 3 China 17 2.8 30 Market Share Status in 2005 Japan : 11 of world’s 50 largest companies, such as Takeda China : Fast market growth ( Increased 28% from 2004 to 2005)
  • 4. C. Outlook • Steady increase of medical expenses: – The price of medicine, due to the aging society – Spread of well-being trend, improvement in quality of life as household income increases – Expanding demand in Quality of Life Drug for chronic diseases such as obesity, hypertension, erectile dysfunction, and diabetes • Expects rapid growth of natural substance based drugs, due to the expansion of preventive and alternative medicine usage
  • 5. 2. Pharmaceutical Industry in Korea A. General Status When compared with GDP, Korea's medical expense is lower than other OECD members (6%) Compared with medical price, it is the highest (28%) With increase of income and change of life style, Korean pharmaceutical market is pursuing Quality of Life Drug, like other developed countries B. History of Domestic Pharmaceutical Industry Secured medical technology in 1960's Established domestic drugs from materials in 1970's Started to develop new drugs in late 1980's Development of antibiotics was major focus until 90's Development of geriatric drug after 2000 Hereafter, to enhance the quality of life, obesity, alopecia, and erectile dysfunction drugs will be the major development of domestic pharmaceutical industry.
  • 6. History of New Drug R&D in Korea Antibiotics (1980’s ~ 1990’s) Drugs for diseases caused by living habit (1990’s ~ Present) QOL Drugs (2000’s and after) Decrease of antibiotic 1980’s: 20% 2001: 15% Due to brief treatment period for antibiotics, they have shorter expiration date Transition from infection treatment drug based market to chronic and geriatric drug based market (Larger emphasis on chronic and geriatric diseases, such as hypertension and diabetes) To follow current life trend, rapid growth of QOL drugs, rather than life related drugs Along with growth of technology, vast possibility of development of erectile dysfunction, obesity and alopecia drugs
  • 7. C. Market size and its structure • Total production of domestic drug market: 9.6 trillion KRW in 2004, 11.3 trillion KRW in 2006 (Actual product sales) – 1.3% of GDP – 1.8% of global market, 11th largest market and rapidly growing. Domestic Market in Global Pharmaceutical Market Year 2000 2001 2002 2003 2004 Share 2.2% 1.8% 1.8% 1.7% 1.8% Sources: Global market, IMS Health, 2005; Korean market, actual product sales in Korea pharmaceutical manufactures association, 2005
  • 8. D. Development of New Drugs • Major development of new drugs after introduction of “Material Patent System” in 1987 – “Sunpla inj.” (SK Pharmaceuticals, ‘99) First domestically developed drug – “Factive” (LG Life Science) FDA approved (April, ‘03) – As of 2007 • Total of 15 drugs were domestically developed and about 40 technologies exported. • Clinical trial for new drugs: about 30 cases • Pre-clinical trial in process: 25 cases • With approval of FDA (U.S.A.), 5~6 new drugs are in clinical trials
  • 9. New Development Projects for Major Korean Companies Products Stages # Products # Companies Phase I 7 7 Phase II 11 9Clinical Trial Phase III 12 7 Preclinical 50 25 New Drugs Discovery 28 14 Others New formulations /Combinations /DDS 75 33 Biotech Medicines 26 16
  • 10. Achievement of New Drug R&D in Korea Indication / Efficacy No. Product Company Approved date 1 Sunpla injection SK chemicals Stomach cancer Sep. 1999 2 EGF topical solution Daewoong Pharm. Co., Ltd. Diabetic antiulcerant May. 2001 3 Milican Dong Wha Pharm. Anti Liver Cancer July. 2001 4 Q-roxin Tablet ChoongWae Pharma Corporation Urinary infection Feb. 2001 5 Joins Tablet SK chemicals Antiarthritis July. 2001 6 Stillen Capsule Dong-A Pharm. Co.,Ltd. Gastritis June. 2002 7 Factive Tablet LG Life Sciences Ltd. Antibiotic Dec. 2002 8 Apitoxin GuJu Pharm. Co., Ltd. Antiarthritis May. 2003 9 Pseudovaxin injection CJ Pseudomonas aeruginosa May. 2003 10 Camtobell injection Chong Kun Dang Pharm. Corp. Anticancer Jan. 2003 11 Revanex Tablet YUHAN Corporation Antiulcer Sep. 2005 12 Zydena Tablet Dong-A Pharm. Co.,Ltd. Erectile Dysfunction Nov. 2005 13 Levovir Capsule Bukwang Pharm.Co.,Ltd. Hepatitis B Nov. 2006 14 Mvix Tablet SK chemicals Erectile Dysfunction July. 2007 Joins Tab., Stillen Tab., and Apitoxin have been classified as natural substance based drugs, and have been excluded from cell treatment
  • 11. E. Infrastructure of Clinical Trials • Established “Good Clinical Practices” in December 1987 • Mandatory in October, 1995 – Adopted ICH GCP standard in Jan. 2000, reinforced subject’s right, its safety protection and the liability of the testers – IND (Investigational new Drug Application) became effective in dec. 2002, establishing the founding stone of Global Harmonization • Total 16 preclinical testing facilities (GLP appointed) for new drug development, and 3 facilities with ability to conduct all stages of the test • Clinical trials is conducted in 119 institutions
  • 12. Current Status of Preclinical Trial October 2008.3 NO SITE 1 KOREA INSTITUTE OF TOXICOLOGY 2 YUHAN RESEARCH INSTITUTE 3 LG LIFE SCIENCES RESEARCH INSTITUTE 4 BIOTOXTECH 5 OCCUPATIONAL SAFETY AND HEALTH RESEARCH INSTITUTE 6 CHEMON PRECLINICAL RESEARCH CENTER 7 AMOREPACIFIC R&D CENTER 8 CLINICAL RESEARCH INSTITUTE SEOUL NATIONAL UNIVERSITY HOSPITAL 9 KOREA TESTING & RESEARCH INSTITUTE 10 MEDVILL 11 BIOCORE 12 IBIOPHARM 13 CENTER FOR BIOSAFETY CATHOLIC UNIVERSITY OF DAEGU 14 CLINICAL RESEARCH INSTITUTE DONGA UNIVERSITY MEDICAL CENTER 15 SEOUL PHARMA LABORATORIES 16 KOREA ENVIRONMENT & MERCHANDISE TESTING INSTITUTE
  • 13. • Established global level infrastructure of clinical trials, along with active development of new drugs and discovery of replacement drugs by the pharmaceutical companies and new venture life science firms – With the increase of global clinical trials, domestic trials also increase rapidly Clinical Trial Status (Numbers of Practice) 2001 2002 2003 2004 2005 2006 2007 Total 45 55 143 136 185 218 281 Domestic Trials 27 38 97 75 90 110 134 Others 18 17 46 61 95 108 147
  • 14. New Drug Development Cases in Korea(1) • Small molecules, approved by FDA – Brand name : Factive tablet/Tablets (Ethical drug) – Company : LG Life Science – Active Ingredient : gemifloxacin mesylate – Indication : synthetic broad-spectrum antibacterial agent – Dosage & Administration : Acute bacterial exacerbation of chronic bronchitis : DOSE-One 320mg tablet daily / DURATION-5 days Community-acquired pneumonia : DOSE-One 320mg tablet daily / DURATION-7 days
  • 15. New Drug Development Cases in Korea(2) • Success of natural substance based development, derived from traditional medicine – Brand name : Stillen Capsules/Tablets (Ethical drug) – Company : Dong-A Pharmaceutical. – Active Ingredient : Extract of Artemisia princeps 60mg – Indication : Gastrointestinal diseases (Gastritis, Prevention of gastritis by NSAID) – Dosage & Administration : 1Tab. Three times daily – Sales : 60 billion KRW in 2007
  • 16. 3. Assessment of Korea’s New Drug Development • One new product every year since 2000 – Products are mostly sold in domestic market – Drugs based on natural substances are more compatible than chemical based • New drugs are developed from initial research stages and showed maximization of potential for successful development – There are limits due to its prolonged time and high risk – Most of the projects in initial research stages are funded by the government • Infrastructure of clinical test has been evaluated to have global competitiveness – Infrastructure needs to be expanded for continuous development of new drugs
  • 17. To contribute to Asian’s health and the region’s economic growth, through maximizing Korean pharmaceutical industry’s strength and complementing its weaknesses From a future-oriented and a long term point of view, Korea, China and Japan need to establish their cooperation by amplifying their similarities and the strengths
  • 18. 4. Direction of Global Development with Korea, China and Japan A. Establish a system to deliver new drugs to the patients immediately among the three nations B. Differentiate from U.S.A., Europe and Japan centered ICH, and shape Global Development with enhanced regional characteristics – Recognize the differences among countries, but suggests that its direction of pharmaceutical industry of the three countries while presenting a future plan – Develop a plan to utilize geographic proximity, cultural and ethnic similarity for global development of science
  • 19. • For global harmonization, Korea has implemented regulations regarding clinical and preclinical trials, authorization (IND, NDA) and production (DMF, GMP) to amend ICH’s suggested guidelines for quality, safety and validity. • Korea has announced “Development of the Pharmaceutical Industry as a New Growth Power” as a government project, promoting global harmonization of the pharmaceutical industry.
  • 20. 6. Role of KFDA Continual pursuit of global harmonization: implementation of ICH guidelines – Introduced ICH GCP (Currently enforced) – Introduced OECD GLP standard (Currently enforced) – DMF system, upgraded cGMP standard (Currently enforced) – Introduced CTD system (Plan to enforce in March ’09 with new drugs) Discovery of Eastern Values: Focus of Korea, China and Japan’s cooperation – Develop plan to reflect Eastern values such as natural substa nce, herbal medicine, etc. – Reflect Asian experience through cooperation of Korea, China, and Japan
  • 21. Share technology and experience centered Asian clinical trial – Participate in expedited new medicine development through cooperative clinical trial among Korea, China, and Japan in order to provide a scientific explanation for differences in ethnicities Cooperation for holding a joint seminar among Korea, China, and Japan pharmaceutical associations and regulatory organizations
  • 22. Operate a Korean professional group to seek Korea, China, and Japan cooperation plan through a Korean professional group – Herbal and natural substance medicine division – Korea, China, and Japan cooperative clinical trial, cross-bridge division • Search for scientific explanation for ethnic differences – Review Process division – Regulation and system harmonization division